Source:http://linkedlifedata.com/resource/pubmed/id/15505608
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
2004-10-26
|
pubmed:abstractText |
Acute graft-versus-host disease, a major obstacle to the overall success of allogeneic hematopoietic stem cell transplantation, is primarily induced by a subset of donor T cells. Most strategies to prevent acute graft-versus-host disease target all T cells regardless of their specificity, and this leads to prolonged posttransplantation immunodeficiency. Selective depletion of alloreactive T cells could spare protective immunity and facilitate engraftment and graft-versus-leukemia effects. Recently described depletion strategies target activation markers such as CD25 that are expressed by alloreactive T cells. However, incomplete depletion may occur when a single surface epitope or pathway of apoptosis is targeted that may not be fully and concurrently expressed among all alloreactive cells. We now report on a novel strategy effective in both cord blood and peripheral blood stem cell alloreactive T cells that simultaneously induces 2 independent pathways of apoptosis after stimulation by recipient dendritic cells or Epstein-Barr virus-transformed B cells. First, we demonstrate that the folate antagonist trimetrexate selectively depletes proliferating alloreactive precursors in vitro in a dose- and time-dependent manner. Similarly, a second agent, denileukin diftitox, kills activated alloreactive T cells expressing CD25. Most importantly, these 2 agents can exert their effects in concert with superior efficacy while sparing resting bystander T cells, which remain available to mount antimicrobial or third-party responses.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Diphtheria Toxin,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Trimetrexate,
http://linkedlifedata.com/resource/pubmed/chemical/denileukin diftitox
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1083-8791
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
10
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
772-83
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:15505608-Antimetabolites, Antineoplastic,
pubmed-meshheading:15505608-Cells, Cultured,
pubmed-meshheading:15505608-Diphtheria Toxin,
pubmed-meshheading:15505608-Fetal Blood,
pubmed-meshheading:15505608-Hematopoietic Stem Cells,
pubmed-meshheading:15505608-Humans,
pubmed-meshheading:15505608-Interleukin-2,
pubmed-meshheading:15505608-Lymphocyte Depletion,
pubmed-meshheading:15505608-Recombinant Fusion Proteins,
pubmed-meshheading:15505608-T-Lymphocytes,
pubmed-meshheading:15505608-Transplantation, Homologous,
pubmed-meshheading:15505608-Trimetrexate
|
pubmed:year |
2004
|
pubmed:articleTitle |
Superior depletion of alloreactive T cells from peripheral blood stem cell and umbilical cord blood grafts by the combined use of trimetrexate and interleukin-2 immunotoxin.
|
pubmed:affiliation |
Department of Pediatrics, Pediatric Stem Cell Transplant Program, Duke University Medical Center, Durham, North Carolina 27705, USA. szabo001@mc.duke.edu
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|